Cytokine inhibitors, including anti‐TNF‐α agents (infliximab, etanercept, adalimumab) and anti‐IL‐17A agents (secukinumab) inhibitors, as well as cytokine receptor inhibitors, such as IL‐6 (tocilizumab) or IL‐α4β7 receptor (vedolizumab) inhibitors, have been investigated for their efficacy in managing steroid‐resistant irAEs in NSCLC.91, 158, 178. The gene discussed is TNF; the disease is non-small cell lung carcinoma.